Stem Cell Therapy for Thromboangiitis Obliterans (Buerger’s Disease)
| Autor: | Kaiti Duan, Alan Dardik, Athena Alipour Faz, Sifon Ndon, Hassan Peyvandi, John A. Persing, Henry C. Hsia, Kyle S. Gabrick, Edward Richardson, Biraja C. Dash |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
thromboangiitis obliterans Pathology medicine.medical_specialty medicine.medical_treatment Bioengineering Disease 030204 cardiovascular system & hematology immunomodulation lcsh:Chemical technology lcsh:Chemistry 03 medical and health sciences angiogenesis 0302 clinical medicine medicine Chemical Engineering (miscellaneous) pluripotent stem cell lcsh:TP1-1185 Therapeutic angiogenesis mesenchymal stem cell Buerger's disease Vascular disease business.industry Process Chemistry and Technology Stem-cell therapy medicine.disease 030104 developmental biology Amputation lcsh:QD1-999 inflammation Stem cell business Vasculitis |
| Zdroj: | Processes, Vol 8, Iss 1408, p 1408 (2020) |
| ISSN: | 2227-9717 |
| Popis: | Buerger’s disease or Thromboangiitis Obliterans (TAO) is a nonatherosclerotic segmental vascular disease which affects small and medium arteries and veins in the upper and lower extremities. Based on pathological findings, TAO can be considered as a distinct form of vasculitis that is most prevalent in young male smokers. There is no definitive cure for this disease as therapeutic modalities are limited in number and efficacy. Surgical bypass has limited utility and 24% of patients will ultimately require amputation. Recently, studies have shown that therapeutic angiogenesis and immunomodulatory approaches through the delivery of stem cells to target tissues are potential options for ischemic lesion treatment. In this review, we summarize the current knowledge of TAO treatment and provide an overview of stem cell-based treatment modalities. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|